Extracellular matrix protein 1 (ECM1), a classical tumour antigen [7, 8] with intrinsic characteristics of overexpression on tumour cell surface to facilitate the recognition of immune cells, could be a good target for therapeutic tumour vaccines. This evidence concerns the gene ECM1 and neoplasm.